Arbor Biotechnologies is a life sciences company at the forefront of discovering and developing novel gene editing technologies. Leveraging a proprietary research engine that integrates machine learning, high-throughput screening, and genome sequencing, Arbor systematically explores nature's diversity to find unique CRISPR-based nucleases and other gene editing tools. Their mission is to create more precise, efficient, and versatile solutions to address a wide range of genetic diseases and advance human health. Arbor focuses on developing both in vivo and ex vivo therapies, aiming to unlock the full potential of genomic medicine.
The Cambridge headquarters serves as the central hub for Arbor's research and development, discovery platform operations, strategic planning, and corporate functions.
Situated in a modern life sciences building, the facility likely houses state-of-the-art laboratories equipped for advanced molecular biology, gene editing, protein engineering, and bioinformatics.
The work culture is characterized by scientific rigor, innovation, collaboration, and a fast-paced, mission-driven environment focused on pioneering new gene editing therapies.
Its location in Cambridge provides Arbor with unparalleled access to leading academic institutions (like MIT and Harvard), a dense network of biotech peers, venture capital, and a highly skilled talent pool, fostering collaboration and accelerating discovery.
While Arbor Biotechnologies's primary operations are centered in Cambridge, MA, its research, potential therapies, and collaborations have global implications. The company engages with the international scientific community through publications, conferences, and potential partnerships. Their focus on developing gene editing tools for diseases impacts patient populations worldwide, and they may pursue clinical trials or commercialization on an international scale in the future.
675 W Kendall St
Cambridge
MA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Arbor Biotechnologies' leadership includes:
Arbor Biotechnologies has been backed by several prominent investors over the years, including:
Arbor Biotechnologies strengthened its leadership team with key appointments in early 2023, including a new CFO and CBO. No major executive departures have been widely publicized in the immediate last 12 months.
Discover the tools Arbor Biotechnologies uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Common email formats at Arbor Biotechnologies likely include [first_initial][last]@arbor.bio or [first].[last]@arbor.bio. These are standard patterns in the biotech industry.
flast@arbor.bio, first.last@arbor.bio
Format
dsmith@arbor.bio (example based on Devyn Smith)
Example
80%
Success rate
Lonza Press Release • October 4, 2023
Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, and Arbor Biotechnologies (Arbor), a biotechnology company discovering and developing the next generation of genetic medicines, today announced an agreement that provides Lonza with access to Arbor’s CRISPR-based gene editing technology....more
Arbor Biotechnologies Press Release • January 10, 2023
Arbor Biotechnologies announced the appointments of Pamela Stetkiewicz, Ph.D., M.B.A., as Chief Financial Officer (CFO) and Kathryn McCabe, Ph.D., as Chief Business Officer (CBO), strengthening its executive team to support growth and strategic objectives....more
Arbor Biotechnologies Press Release • July 28, 2021
Arbor Biotechnologies announced the successful completion of a $215 million Series B financing round. The funding will be used to advance its portfolio of precision genetic medicines, further develop its novel gene editing technologies, and expand its discovery platform....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Arbor Biotechnologies, are just a search away.